Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtre
Ajouter des filtres








Gamme d'année
1.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 38(1): 65-72, Jan.-Mar. 2016. tab, graf
Article Dans Anglais | LILACS | ID: lil-776489

Résumé

Objective: To conduct a systematic literature review of animal and human studies reporting anxiolytic or antidepressive effects of ayahuasca or some of its isolated alkaloids (dimethyltryptamine, harmine, tetrahydroharmine, and harmaline). Methods: Papers published until 3 April 2015 were retrieved from the PubMed, LILACS and SciELO databases following a comprehensive search strategy and using a predetermined set of criteria for article selection. Results: Five hundred and fourteen studies were identified, of which 21 met the established criteria. Studies in animals have shown anxiolytic and antidepressive effects of ayahuasca, harmine, and harmaline, and experimental studies in humans and mental health assessments of experienced ayahuasca consumers also suggest that ayahuasca is associated with reductions in anxiety and depressive symptoms. A pilot study reported rapid antidepressive effects of a single ayahuasca dose in six patients with recurrent depression. Conclusion: Considering the need for new drugs that produce fewer adverse effects and are more effective in reducing anxiety and depression symptomatology, the described effects of ayahuasca and its alkaloids should be further investigated.


Sujets)
Humains , Animaux , Rats , Anxiolytiques/pharmacologie , Banisteriopsis , Antidépresseurs/pharmacologie , Anxiété/traitement médicamenteux , Anxiolytiques/usage thérapeutique , N,N-Diméthyl-tryptamine/pharmacologie , Trouble dépressif/traitement médicamenteux , Harmaline/pharmacologie , Harmine/pharmacologie , Souris , Antidépresseurs/usage thérapeutique
2.
Braz. J. Psychiatry (São Paulo, 1999, Impr.) ; 37(1): 13-20, Jan-Mar/2015. tab, graf
Article Dans Anglais | LILACS | ID: lil-741933

Résumé

Objectives: Ayahuasca (AYA), a natural psychedelic brew prepared from Amazonian plants and rich in dimethyltryptamine (DMT) and harmine, causes effects of subjective well-being and may therefore have antidepressant actions. This study sought to evaluate the effects of a single dose of AYA in six volunteers with a current depressive episode. Methods: Open-label trial conducted in an inpatient psychiatric unit. Results: Statistically significant reductions of up to 82% in depressive scores were observed between baseline and 1, 7, and 21 days after AYA administration, as measured on the Hamilton Rating Scale for Depression (HAM-D), the Montgomery-Åsberg Depression Rating Scale (MADRS), and the Anxious-Depression subscale of the Brief Psychiatric Rating Scale (BPRS). AYA administration resulted in nonsignificant changes in Young Mania Rating Scale (YMRS) scores and in the thinking disorder subscale of the BPRS, suggesting that AYA does not induce episodes of mania and/or hypomania in patients with mood disorders and that modifications in thought content, which could indicate psychedelic effects, are not essential for mood improvement. Conclusions: These results suggest that AYA has fast-acting anxiolytic and antidepressant effects in patients with a depressive disorder. .


Sujets)
Adulte , Femelle , Humains , Mâle , Adulte d'âge moyen , Antidépresseurs/usage thérapeutique , Banisteriopsis/composition chimique , Trouble dépressif/traitement médicamenteux , Hallucinogènes/usage thérapeutique , Phytothérapie , Analyse de variance , Anxiolytiques/usage thérapeutique , Échelle abrégée d'appréciation psychiatrique , Harmine/usage thérapeutique , N,N-Diméthyl-tryptamine/usage thérapeutique , Indice de gravité de la maladie , Facteurs temps , Résultat thérapeutique
SÉLECTION CITATIONS
Détails de la recherche